Thermo Fisher Expands U.S. Drug-Device Manufacturing with SHL Medical Partnership
Event summary
- Thermo Fisher Scientific has partnered with SHL Medical to integrate sterile manufacturing and autoinjector assembly at its Ridgefield, NJ site.
- The collaboration focuses on SHL Medical’s Molly® autoinjector platform, combining it with Thermo Fisher’s sterile fill-finish capabilities.
- Thermo Fisher acquired the Ridgefield facility from Sanofi in September 2025 to bolster its U.S. manufacturing footprint.
- The expansion includes increased capacity for pre-filled syringe (PFS) fill-finish and device assembly.
The big picture
Thermo Fisher’s collaboration with SHL Medical and expansion in Ridgefield align with the broader industry shift toward patient-centric, self-administered therapies. The move strengthens Thermo Fisher’s position as a key player in sterile manufacturing and drug-device combination products, particularly for autoimmune and chronic disease treatments. With annual revenue exceeding $40 billion, Thermo Fisher is leveraging this partnership to simplify supply chains and accelerate timelines for its biopharmaceutical customers.
What we're watching
- Market Demand
- How the growing demand for self-administered injectable therapies will impact Thermo Fisher’s revenue growth.
- Execution Risk
- Whether Thermo Fisher can sustain operational efficiency while scaling its integrated manufacturing solutions.
- Competitive Positioning
- The pace at which competitors adopt similar integrated drug-device manufacturing models.
Related topics